SCHEMBL2089934

SCHEMBL2089934

[CH2]CCCCOC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10534586 0.98 TSHR (0.43)
SCHEMBL1416162 0.98 TSHR (0.43)
SCHEMBL1415947 0.92
SCHEMBL2746597 0.87 TSHR (0.52)
SCHEMBL2059697 0.84 TSHR (0.50)
SCHEMBL2136691 0.84 TSHR (0.50)
SCHEMBL31296577 0.84 TSHR (0.50)
SCHEMBL2746089 0.84 TSHR (0.50)
SCHEMBL5721317 0.84 TSHR (0.50)
SCHEMBL2139712 0.84 TSHR (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756096-B1 INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-08-12 EP claimed
EP-0957908-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2003-03-12 EP claimed
EP-1023295-A4 FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS MERCK & CO INC (US) 2001-01-24 EP claimed
EP-1061934-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-12-27 EP claimed
EP-1023295-A1 FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS Merck & Co., Inc. (US) 2000-08-02 EP claimed
EP-0957908-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1999-11-24 EP claimed
US-5981584-A USEFUL IN THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS, INHIBITING ANGIOGENESIS, INHIBITING OSTEOCLAST MEDIATED BONE RESORPTION, PREVENTING PLATELET THROMBOSIS MERCK & CO., INC. (US) 1999-11-09 US claimed
WO-1999045939-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-09-16 WO claimed
US-5945545-A SUBSTITIUTED AMIDINOBENZENE COMPOUNDS; ANTICOAGULANTS MERCK & CO., INC. (US) 1999-08-31 US claimed
WO-1998034935-A1 FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS MERCK & CO., INC. (US) 1998-08-13 WO claimed
WO-1998025601-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-06-18 WO claimed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
CN-100497345-C 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2009-06-10 CN disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
US-5981584-A USEFUL IN THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS, INHIBITING ANGIOGENESIS, INHIBITING OSTEOCLAST MEDIATED BONE RESORPTION, PREVENTING PLATELET THROMBOSIS MERCK & CO., INC. (US) 1999-11-09 US disclosed
WO-1999045939-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-09-16 WO disclosed
US-5945545-A SUBSTITIUTED AMIDINOBENZENE COMPOUNDS; ANTICOAGULANTS MERCK & CO., INC. (US) 1999-08-31 US disclosed
WO-1998034935-A1 FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS MERCK & CO., INC. (US) 1998-08-13 WO disclosed
WO-1998025601-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-06-18 WO disclosed